Q-omics provides the consensus-scored TRAPPC2B profile across patient tissues and cancer cell-line models. TRAPPC2B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAPPC2B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TRAPPC2B RNA expression shows 18,533 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where TRAPPC2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC2B survival associations across molecular data types. TRAPPC2B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC2B RNA expression–survival associations across cancer types. High TRAPPC2B expression shows unfavorable associations in HNSC, CESC, ACC, UVM and READ, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAPPC2B RNA expression.
This table summarizes TRAPPC2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAPPC2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC2B shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, LIHC, HNSC and BRCA. The KIRC box plot shows higher TRAPPC2B RNA expression in tumor versus normal tissue (log2 FC = +0.584, t-test p < 0.001).
This table shows molecular features associated with TRAPPC2B in patient tissues and cancer cell lines. In patient samples, TRAPPC2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
